FAQ
Log In
Wednesday 26th November 2014
News
 › 
 › 

Gastrointestinal cancer drug shows promise

4th April 2012

Bayer has said that its cancer drug has improved chances of survival in patients suffering from a type of gastrointestinal tumour and kept the condition from worsening, following a 199-patient late-stage trial.

Findings showed that a combination of Bayer’s tumour-fighting drug regorafenib and best supportive care prolonged survival in patients with metastatic gastrointestinal stromal tumours or GIST, when compared with a dummy drug and best supportive care. Bayer now plans to file for US approval for regorafenib to treat metastatic GIST.

 

Share this page

Comments

There are no comments for this article, be the first to comment!


Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2014